This post was originally published on this site
J&J projects 5-6% revenue growth in 2024, fueled by strong core businesses, acquisitions, and a robust pipeline targeting $57 billion in drug sales by 2025.
December 6
Johnson & Johnson’s prescription for growth
0 comments